Calcium signaling underlies much of physiology. Almost all the Ca2+ in the cytoplasm is
bound to buffers, with typically only∼ 1% being freely ionized at resting levels in most cells …

Changes of intracellular Ca2+ concentration regulate many aspects of cardiac myocyte
function. About 99% of the cytoplasmic calcium in cardiac myocytes is bound to buffers, and …

Hypertrophic cardiomyopathy (HCM) is often caused by single sarcomeric gene mutations
that affect muscle contraction. Pharmacological correction of mutation effects prevents but …

One of the obstacles in studying the pathogenesis of hypertrophic cardiomyopathy (HCM) is
the poor availability of myocardial tissue samples at the early stages of disease …

In the last few decades, many pathogenic or likely pathogenic genetic mutations in over
hundred different genes have been described for non-ischemic, genetic cardiomyopathies …

Noonan syndrome (NS), the most common among RASopathies, is caused by germline
variants in genes encoding components of the RAS-MAPK pathway. Distinct variants …

Life-threatening ventricular arrhythmias are the main clinical burden in patients with
hypertrophic cardiomyopathy (HCM), and frequently occur in young patients with mild …

Omecamtiv mecarbil (OM) is a promising novel drug for improving cardiac contractility. We
tested the therapeutic range of OM and identified previously unrecognized side effects. The …

In this perspective, we discussed emerging data indicating a role for Notch signalling in
inherited disorders of the heart failure with focus on hypertrophic cardiomyopathy (HCM) …

Cardiomyocytes derived from human induced pluripotent stem cells (iPSCs) provide a
unique opportunity to understand the pathophysiological effects of genetic cardiomyopathy …